AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04428099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Information
Description: Written information about lifestyle change suggestions
Study NCT04321798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
Study NCT02858648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior intervention with smart phone based self-monitoring
Description: Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
Study NCT02858648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior intervention with paper diary based self-monitoring
Description: Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
Study NCT04072549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free Summer Programming
Description: The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
Study NCT04467359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Optimize physical conditions; Fasting solid diet 6h before surgery, fasting clear fluid 2 h before surgery; If there is no chief complaint of dizziness, nausea or other discomfort after the operation, warm water (no more than 100ml) can be immediately drunk. Pain management; Encourage patients to engage in early activities under the premise of effective pain control; If no dural puncture and other complications occur, the patient has no chief complaints of headache, dizziness, nausea and other discomfort, and there is no need to lie supine, the comfortable position such as semi-supine lateral supine position can be taken immediately (avoid 90-degree upright position for patients with hip joint); Prevention of thrombosis; Prevention and treatment of nausea and vomiting; Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the operation.
Study NCT04467359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Perioperative routine rehabilitation nursing
Description: Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
Study NCT04467359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative routine rehabilitation nursing
Description: Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
Study NCT03946020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration with or without autologous bone
Description: Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
Study NCT03946020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided bone regeneration with or without autologous bone
Description: Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
Study NCT01606059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-0920
Description: Dosage form: Extended release tablet Dosage: 2 tablets
Study NCT02348190 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lipid/heparin
Description: 32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs.
Study NCT02348190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipid/heparin
Description: 32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs.
Study NCT01270529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing Physical activity
Description: The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
Study NCT03279107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber
Description: soluble corn fiber
Study NCT03279107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltodextrin
Description: maltodextrin
Study NCT01344343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated surgical hip fracture repair
Description: Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
Study NCT02224170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
Study NCT02224170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
Study NCT03817398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT03817398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Withdrawn
Description: Stop taking TKI medication
Study NCT03817398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03817398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03817398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor
Description: Re-start TKI medication
Study NCT04095234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.
Study NCT04095234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
Study NCT04585750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.
Study NCT04585750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
Study NCT04376593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-αvβ6-BP
Description: Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).
Study NCT04053816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Study NCT05507749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoballoon ablation
Description: Cryoballoon ablation for the treatment of atrial fibrillation
Study NCT04555759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-minute walk test
Description: The patients will do a 2-minute walk test, using their walking aids or braces
Study NCT03292237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition
Description: Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
Study NCT04790500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobilization technique
Description: Mobilization of sacroiliac joint which will increase the range of motion and reduction in pain and improvement in functional limitation.
Study NCT04790500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: Muscle energy technique it is known as active muscular relaxation technique. It helps in lengthening the shorten muscle and increasing range of restricted muscles
Study NCT02612246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 single ascending doses
Description: single dose, oral solution
Study NCT02612246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: single dose, oral solution, matching placebo
Study NCT02612246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 multiple ascending doses
Description: multiple doses, daily for 14 days, oral solution
Study NCT02612246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple doses
Description: multiple doses, daily for 14 days, oral solution
Study NCT00754884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmon calcitonin
Description: daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
Study NCT00754884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal saline solution plus glycerol
Description: daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
Study NCT03721250 — intervention group
Intervention type: OTHER
Intervention: epidural
Description: thoracic epidural analgesia
Study NCT04232852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic mix
Description: The probiotic mix will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule.
Study NCT04232852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive an identical capsule of maltodextrin.
Study NCT05507749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implantable loop recorder insertion
Description: The device called a implantable loop recorder, is placed just under the skin of one's chest during a minor surgery.
Study NCT00432094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)
Study NCT00432094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
Study NCT00432094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
Study NCT01763021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
Study NCT02433964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grupo LED
Study NCT01763021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
Study NCT02178501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA
Description: comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
Study NCT02178501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 PUFA
Description: comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
Study NCT02473003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity exercise
Description: high intensity exercise 80-90%
Study NCT01606059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-0919
Description: Dosage form: Extended release tablet Dosage: 1 tablet
Study NCT02549794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT angiography with high concentration contrast agent
Description: Standard concentration of iodine contrast agent for CT
Study NCT02549794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT angiography with low concentration contrast agent (320)
Description: Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
Study NCT02549794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT angiography with low concentration contrast agent (270)
Description: Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
Study NCT01051713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Supported
Description: Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
Study NCT01051713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits.
Study NCT01638650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
Description: in accordance with current clinical HIV treatment guidelines
Study NCT01638650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg bid orally, Days 1-14
Study NCT01638650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir [Invirase]
Description: 500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
Study NCT04557176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP, point-of-care assay
Description: CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
Study NCT02433964 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ledterapia off + price
Study NCT00077584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg
Description: Oral tablets containing 62.5 mg of bosentan
Study NCT00077584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Description: Oral tablets containing 125 mg of bosentan
Study NCT00077584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
Study NCT00507546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: 8 mg nightly
Study NCT00507546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nightly 8mg of placebo (same appearance as ramelteon)
Study NCT03338842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distractor and Lower limb VR
Description: In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
Study NCT03201354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Filtration surgery with Ex-PRESS
Description: Filtration surgery with Ex-PRESS
Study NCT03201354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non penetrating deep sclerectomy
Description: Non penetrating deep sclerectomy
Study NCT03201354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract extraction
Description: Cataract surgery and IOL implantation
Study NCT02141321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT01866969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01866969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02473003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low/medium intensity exercise
Description: low/medium intensity exercise 40-50%
Study NCT02473003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral medicine strategies
Description: Motivational and self-regulatory behavioral medicine support strategies
Study NCT02513784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
Study NCT03280342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR-TPM (Topamax)
Description: XR-TPM (Trokendi XR)
Study NCT03280342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-TPM (Trokendi XR)
Description: XR-TPM (Trokendi XR)
Study NCT05038748 — intervention group
Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5